ST. LOUIS, June 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL - News), a $1.7 billion Life Science company, and Oxford BioMedica (LSE: OXB - News), a leading gene therapy company, have announced today that they have filed a lawsuit against Open Biosystems, Inc. for infringement of key patents that cover key lentiviral-based systems for delivery of foreign DNA to a broad array of mammalian cells. The complaint, which was filed in U.S. District Court Eastern District of Missouri, alleges that Open Biosystems is infringing U.S. Patent Nos. 6924123 and 7056699. Rights to the patents, both entitled Lentiviral LTR Deleted Vector, were exclusively licensed for research use to Sigma-Aldrich by Oxford BioMedica in October 2005.
